Carlos A. Santos

Dr. Carlos A. Santos


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Transplantation Direct
Verified
Journal Article
Open access
CSCarlos A. Santos
Carlos A. Santos
RHRichard S. Hotchkiss
Richard S. Hotchkiss
WCWilliam C. Chapman
William C. Chapman
MOMargaret A. Olsen
Margaret A. Olsen
Background. Although some studies have examined the epidemiology of bloodstream infections after liver transplantation, they were based in single centers and did not identify bloodstream infections treated in other hospitals. Methods. We retrospectively examined a cohort of 7912 adult liver transplant recipients from 24 transplant centers using 2004 to 2012 International Classification of Diseases, Ninth Revision, Clinical Modification billing data from 3 State Inpatient Databases, and identified bloodstream infections, inpatient death, and cumulative 1-year hospital costs. Multilevel Cox regression analyses were used to determine factors associated with bloodstream infections and death. Results. Bloodstream infections were identified in 29% (n = 2326) of liver transplant recipients, with a range of 19% to 40% across transplant centers. Only 63% of bloodstream infections occurring more than 100 days posttransplant were identified at the original transplant center. Bloodstream infections were associated with posttransplant laparotomy (adjusted hazard ratio [aHR], 1.52), prior liver transplant (aHR, 1.42), increasing age (aHR, 1.07/decade), and some comorbidities. Death was associated with bloodstream infections with and without septic shock (aHR, 10.96 and 3.71, respectively), transplant failure or rejection (aHR, 1.41), posttransplant laparotomy (aHR, 1.40), prior solid-organ transplant (aHR, 1.48), increasing age (aHR, 1.15/decade), and hepatitis C cirrhosis (aHR, 1.20). The risk of bloodstream infections and death varied across transplant centers. Median 1-year cumulative hospital costs were higher for patients who developed bloodstream infections within 1 year of transplant compared with patients who were bloodstream infection-free (US $229 806 vs US $111 313; P < 0.001). Conclusions. Bloodstream infections are common and costly complications after liver transplantation that are associated with a markedly increased risk of death. The incidence and risk of developing bloodstream infections may vary across transplant centers.

5 May 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PNPuja H Nambiar
Puja H Nambiar
TLTao Liang
Tao Liang
NLNazzarena Labo
Nazzarena Labo
JHJonathan M. Hand
Jonathan M. Hand
EBEmily A Blumberg
Emily A Blumberg
CDChristine M Durand
Christine M Durand
Background: Due to high prevalence of Kaposi sarcoma–associated herpesvirus (KSHV) among people with human immunodeficiency virus (HIV), KSHV-associated disease (KAD) may be increased after kidney transplantation from donors with HIV (HIV D+) to recipients with HIV (HIV R+). Methods: Anti-KSHV antibodies were measured in HIV R+ and donors with and without HIV (HIV D–) using a 30-antigen multiplex assay within 3 multicenter kidney transplantation studies. KSHV seropositivity was defined as reactivity to conventional KSHV antigens (≥1 ORF73 or K8.1); reactivity to expanded 5-antigen and 30-antigen panels were also reported. Risk factors were identified using modified Poisson regression. Recipients were monitored for posttransplant anti-KSHV antibody changes and KAD. Results: KSHV seroprevalence was 40.6% (143/352) among HIV R+, 25.2% (33/131) among HIV D+, and 7.5% (4/53) among HIV D–. In the multivariable model, only men who have sex with men (MSM) status was associated with KSHV seropositivity (relative risk, 1.51 [95% confidence interval {CI}, 1.07–2.14] in recipients and 2.39 [95% CI, 1.03–5.53] in donors). Among 418 HIV R+ (215 HIV D+/R+, 203 HIV D–/R+), there were 5 KAD cases (incidence, 0.63 cases/100 person-years [95% CI, .26–1.52]): 3 skin-only Kaposi sarcoma (KS), 1 multicentric Castleman disease, and 1 allograft KS. The allograft KS occurred in a female HIV D+/R+ and was likely donor derived. Remaining KAD cases occurred in male HIV D–/R+ and were likely recipient KSHV reactivation or acquisition. Conclusions: In the United States, KSHV seroprevalence in donors and recipients with HIV was high, particularly among MSM. Reassuringly, KSHV-associated disease was rare and primarily attributed to recipient rather than donor-derived KSHV.

1 September 2016 in Seminars in Nephrology
Verified
Journal Article
Closed access
CSCarlos A. Santos
Carlos A. Santos

21 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CSCarlos A. Santos
Carlos A. Santos
YRYoona Rhee
Yoona Rhee
MCMichael T. Czapka
Michael T. Czapka
AKAamir S. Kazi
Aamir S. Kazi
LPLaurie A. Proia
Laurie A. Proia
Hematopoietic stem cell transplant recipients are at increased risk of infection and immune dysregulation due to reception of cytotoxic chemotherapy; development of graft versus host disease, which necessitates treatment with immunosuppressive medications; and placement of invasive catheters. The prevention and management of infections in these vulnerable hosts is of utmost importance and a key “safety net” in stem cell transplantation. In this review, we provide updates on the prevention and management of CMV infection; invasive fungal infections; bacterial infections; Clostridium difficile infection; and EBV, HHV-6, adenovirus and BK infections. We discuss novel drugs, such as letermovir, isavuconazole, meropenem-vaborbactam and bezlotoxumab; weigh the pros and cons of using fluoroquinolone prophylaxis during neutropenia after stem cell transplantation; and provide updates on important viral infections after hematopoietic stem cell transplant (HSCT). Optimizing the prevention and management of infectious diseases by using the best available evidence will contribute to better outcomes for stem cell transplant recipients, and provide the best possible “safety net” for these immunocompromised hosts.

3 February 2016 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
CSCarlos A. Santos
Carlos A. Santos
DBDaniel C. Brennan
Daniel C. Brennan
MSMohammed J. Saeed
Mohammed J. Saeed
VFVictoria J. Fraser
Victoria J. Fraser
MOMargaret A. Olsen
Margaret A. Olsen

1 October 2006 in AIDS Care
Verified
Journal Article
Closed access
CSCarlos A. Santos
Carlos A. Santos
OAO. Adeyemi
O. Adeyemi
ATA. R. Tenorio
A. R. Tenorio
Directly administered antiretroviral therapy (DAART) is one approach to improve adherence among HIV-positive individuals. DAART has been assessed for confined participants such as prisoners and for patients enrolled in methadone clinics but community-based voluntary DAART programs are not well studied. We examined the attitudes toward DAART among 47 HIV-positive inpatients in an inner city public hospital, a population difficult to engage in conventional self-administered highly active antiretroviral therapy (HAART). This study found that 83% of participants prefer self-administered therapy (SAT) and only 17% elect for DAART. A significant proportion of participants think the approach is intrusive or impractical and few are willing to meet with providers daily. A proportion of our patients, however, struggle with medication non-adherence and fragmented medical care, evident in the high rates of missed clinic appointments, frequent emergency department visits and repeated hospitalizations. These data can inform the development of DAART programs and suggest that considerable effort is needed to 'sell' the idea of DAART to this patient population. It is likely that such patients will greatly benefit from a clinic that can provide intensive counseling, frequent follow-up, home visits and DAART. Patient education regarding the merits of such an approach will be key to success.